# OnCo record alk-negative-anaplastic-large-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/alk-negative-anaplastic-large-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "alk-negative-anaplastic-large-cell-lymphoma" ;
  schema:name "ALK-negative anaplastic large cell lymphoma"@en ;
  schema:alternateName "ALK-negative ALCL"@en, "ALK- ALCL"@en, "Anaplastic large cell lymphoma, ALK-negative"@en, "ALK-negative ALCL (DUSP22, TP63 subsets)"@en, "Systemic ALK-negative anaplastic large cell lymphoma"@en ;
  schema:description "An aggressive T-cell lymphoma that looks like its ALK-positive sibling under the microscope and carries the same CD30 marker, but lacks the broken ALK gene. It affects older people and is cured less often, and several genetic changes inside it predict very different outcomes."@en ;
  schema:url <https://onco.cc/cancers/alk-negative-anaplastic-large-cell-lymphoma/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anaplastic_large-cell_lymphoma> ;
  schema:citation <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://doi.org/10.1016/j.annonc.2021.12.002>, <https://doi.org/10.1038/bjc.2015.94>, <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq> ;
  onco:tag "heme", "lymphoma", "subtype-page" ;
  onco:related <https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/primary-cutaneous-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/breast-implant-associated-alcl/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:terms <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-pit-score/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-b-versus-t-cell/> ;
  onco:trials <https://onco.cc/trials/echelon-2/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/alk/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/trials/echelon-2/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> .